Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 718K | 2M | 755K |
| Gross Profit | 1M | 563K | 372K | 1M | 700K |
| Operating Income | 5M | -4M | -4M | -4M | -2M |
| EBITDA | -4M | -3M | -3M | -8M | -987K |
| Net Income | -5M | -4M | -4M | -8M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0132
+0.00% today
1Y Change
-53.27%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rapid Dose Therapeutics Corp. (RDTCF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.01 and down 53.3% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +104.4%, EPS growth of +2.4%, a dividend yield of 0.0%. What stands out right now is revenue +104.4%, EPS +2.4%, free cash flow +49.8% with operating margin -110.7% and ROIC 543.8%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RDTCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDTCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RDTCF Max Drawdown
-56.60%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RDTCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$755.2K
-56.9% YoY
FY Net Income
-$1.8M
+78.7% YoY
Free Cash Flow
-$1.6M
+46.3% YoY
Revenue Growth
+104.4%
EPS Growth
+2.4%
Gross Margin
29.8%
Net Margin
-157.2%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 718K | 2M | 755K |
| Gross Profit | 1M | 563K | 372K | 1M | 700K |
| Operating Income | 5M | -4M | -4M | -4M | -2M |
| EBITDA | -4M | -3M | -3M | -8M | -987K |
| Net Income | -5M | -4M | -4M | -8M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21K | 161K | 28K | 34K | 70K |
| Total Assets | 2M | 2M | 2M | 3M | 4M |
| Total Liabilities | 7M | 5M | 5M | 3M | 5M |
| Shareholder Equity | -5M | -3M | -3M | 252K | -1M |
| Total Debt | 3M | 2M | 2M | 1M | 2M |
| Net Debt | 3M | 2M | 2M | 1M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+45.9% YoY
Capital Expenditures
9K
+77.4% YoY
Free Cash Flow
2M
+46.3% YoY
Key ratios
Gross Margin
29.8%
Operating Margin
-110.7%
Net Margin
-157.2%
ROE
75.8%
Debt / Equity
-1.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.